½ÃÀ庸°í¼­
»óǰÄÚµå
1607171

¼¼°èÀÇ À¯ÀüÀÚ ÆÐ³Î ½ÃÀå : ±â¼ú, Á¦Ç°, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Gene Panel Market by Technique (Microarray, Next-Generation Sequencing, Polymerase Chain Reaction), Product (Test Kits, Testing Services), Application, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 193 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

À¯ÀüÀÚ ÆÐ³Î ½ÃÀåÀº 2023³â¿¡ 31¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 34¾ï 1,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.99%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 60¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

À¯ÀüÀÚ ÆÐ³ÎÀº Â÷¼¼´ë ½ÃÄö¼­ ±â¼úÀ» »ç¿ëÇÏ¿© µ¿½Ã¿¡ °Ë»çµÇ´Â À¯ÀüÀÚÀÇ ¸ðÀ½ÀÔ´Ï´Ù. ÆÐ³ÎÀÇ Çʿ伺Àº ½Å¼ÓÇϰí Á¾ÇÕÀûÀÎ À¯Àü ÇÐÀû ÅëÂû·ÂÀ» Á¦°øÇϸç Áø´Ü ÇÐÀ§¿Í Ä¡·áÀÇ °³º°È­¸¦ Çâ»ó½ÃŰ´Â ´É·Â¿¡¼­ À¯·¡ÇÕ´Ï´Ù. ½Ã³ª¸®¿À¿¡¼­ À¯ÀüÀÚ ÆÐ³ÎÀº ÀÓ»ó Áø´Ü, ¿¬±¸ ±â°ü, º´¿ø, ƯÈ÷ Á¾¾çÇÐ ¹× Èñ±ÍÁúȯ ºÐ¾ß¿¡¼­ ÇʼöÀûÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 31¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 34¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 60¾ï 6,000¸¸ ´Þ·¯
CAGR(%) 9.99%

½ÃÀå ¼ºÀåÀº °³ÀÎÈ­ ÀÇÇп¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ½ÃÄö½Ì ±â¼úÀÇ Áøº¸, ¿¬±¸ ÀÚ±Ý Áõ°¡ÀÇ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. °³ÀÎÀÇ À¯ÀüüÇп¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó, ¼ÒºñÀÚ Á÷Á¢ À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ °ü½ÉÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù.¿¡ ´ëÇÑ ÅõÀÚ¿Í Á¤»óÀûÀÎ Áø·á¿¡ °Ë»ç¸¦ ÅëÇÕÇϱâ À§ÇÑ ÀÇ·á Á¦°ø¾÷ü¿ÍÀÇ Çù·Â µîÀÌ ÀÖ½À´Ï´Ù.

±×·¯³ª °Ë»ç ºñ¿ëÀÇ »ó½Â, º¹ÀâÇÑ µ¥ÀÌÅÍ ºÐ¼®, ±ÔÁ¦ »óȲ µîÀÇ °úÁ¦°¡ ½ÃÀå ¼ºÀåÀÇ ¹æÇذ¡ µÇ°í ÀÖ½À´Ï´Ù. ¼¼°è ½ÃÀå È®´ë¸¦ ÀúÇØÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.»ç¾÷ ¼ºÀåÀ» À§ÇÑ Çõ½ÅÀûÀÎ ºÐ¾ß·Î´Â ºñ¿ë È¿À²ÀûÀÎ Á¾ÇÕÀû ÆÐ³ÎÀÇ °³¹ß, ÇØ¼® ÇÁ·Î¼¼½º¸¦ ÇÕ¸®È­Çϱâ À§ÇÑ µ¥ÀÌÅÍ ºÐ¼®¿¡ÀÇ ÀΰøÁö´ÉÀÇ Ã¤¿ëÀ» µé ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº Áúº´ÀÔ´Ï´Ù. µ¹¿¬º¯À̻Ӹ¸ ¾Æ´Ï¶ó, º¸´Ù ³ªÀº ¾à¹° ¹ÝÀÀÀ» À§ÇÑ ¾à¸® À¯ÀüüÇеµ Ÿ°ÙÀ¸·Î ÇÏ´Â ÆÐ³ÎÀÇ ÀÛ¼º¿¡ ÁÖ·ÂÇÒ ¼ö ÀÖ¾î, ¸ÂÃãÇü ÀÇ·áÀÇ µ¿ÇâÀ» °­È­ÇÒ ¼ö°¡ ÀÖ½À´Ï´Ù. ¾÷°ú Çмú¿¬±¸±â°ü°úÀÇ ÆÄÆ®³Ê½ÊÀ» È®´ëÇÔÀ¸·Î½á Áøº¸¿Í ½ÃÀå È®´ë¸¦ È¿°úÀûÀ¸·Î ÃßÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â À¯ÀüÀÚ ÆÐ³Î ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

À¯ÀüÀÚ ÆÐ³Î ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿Àû ÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • À¯Àü¼º Áúȯ ¹× Èñ±ÍÁúȯÀÇ ±ÞÁõ
    • °³º°È­ ÀǾàǰ¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡
    • ¾Ï Áø·á¿¡¼­ÀÇ ´ÙÁß À¯ÀüÀÚ ÆÐ³Î °Ë»çÀÇ ±Þ¼ÓÇÑ º¸±Þ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • À¯ÀüÀÚ µ¥ÀÌÅÍÀÇ º¸¾È È®º¸ÀÇ ¹®Á¦
  • ½ÃÀå ±âȸ
    • Áý´Ü ½ÃÄö½Ì¿¡ ´ëÇÑ Á¤ºÎÀÇ Àû±ØÀûÀÎ ´ëó
    • ÀÓ»ó ¿¬±¸¿ë Â÷¼¼´ë ½ÃÄö½Ì¿¡ ±âÃÊÇÑ »õ·Î¿î À¯ÀüÀÚ ÆÐ³ÎÀÇ ¼Ò°³
  • ½ÃÀåÀÇ °úÁ¦
    • Áø´Ü °Ë»ç¿¡ À־ÀÇ Á¤¹Ðµµ¿¡ ´ëÇÑ ¿ì·Á¿Í Ç¥ÁØÈ­ÀÇ ¹®Á¦

Porter's Five Force : À¯ÀüÀÚ ÆÐ³Î ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Force Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÆÄ¾ÇÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Force Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂûÀ» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : À¯ÀüÀÚ ÆÐ³Î ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº À¯ÀüÀÚ ÆÐ³Î ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : À¯ÀüÀÚ ÆÐ³Î ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

À¯ÀüÀÚ ÆÐ³Î ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ºÐ¸í ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õ´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÑ Áö°ß À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : À¯ÀüÀÚ ÆÐ³Î ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â À¯ÀüÀÚ ÆÐ³Î ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±âº» °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐ·ùÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå : À¯ÀüÀÚ ÆÐ³Î ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ °æ·Î¸¦ ±×¸³´Ï´Ù.

À¯ÀüÀÚ ÆÐ³Î ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϰí, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • À¯Àü¼º Áúȯ°ú Èñ±ÍÁúȯÀÇ ±ÞÁõ
      • °³ÀÎÈ­µÈ ÀǾàǰ¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡
      • Á¾¾çÇÐ Áø·á¿¡ À־ÀÇ ´ÙÁß À¯ÀüÀÚ ÆÐ³Î °Ë»çÀÇ ±Þ¼ÓÇÑ µµÀÔ
    • ¾ïÁ¦¿äÀÎ
      • À¯ÀüÀÚ µ¥ÀÌÅÍÀÇ º¸¾È È®º¸¿¡ °üÇÑ ¹®Á¦
    • ±âȸ
      • Áý´Ü ½ÃÄö½Ì¿¡ ´ëÇÑ Á¤ºÎÀÇ ¹Ù¶÷Á÷ÇÑ ´ëó
      • ÀÓ»óÁ¶»ç¸¦ À§ÇÑ Â÷¼¼´ë ½ÃÄö½Ì¿¡ ±âÃÊÇÑ »õ·Î¿î À¯ÀüÀÚ ÆÐ³ÎÀÇ ¼Ò°³
    • °úÁ¦
      • Áø´Ü °Ë»ç¿¡ À־ÀÇ Á¤¹ÐµµÀÇ ¿ì·Á¿Í Ç¥ÁØÈ­ÀÇ ¹®Á¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå À¯ÀüÀÚ ÆÐ³Î ½ÃÀå : ±â¼úº°

  • ¸¶ÀÌÅ©·Î¾î·¹ÀÌ
  • Â÷¼¼´ë ½ÃÄö½Ì
  • ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ

Á¦7Àå À¯ÀüÀÚ ÆÐ³Î ½ÃÀå : Á¦Ç°º°

  • °Ë»ç ŰƮ
  • Å×½ºÆ® ¼­ºñ½º

Á¦8Àå À¯ÀüÀÚ ÆÐ³Î ½ÃÀå : ¿ëµµº°

  • ¾Ï Áø´Ü
  • À¯Àü¼º Áúȯ
  • °¨¿°Áõ
  • ¾à¸® À¯ÀüüÇÐ

Á¦9Àå À¯ÀüÀÚ ÆÐ³Î ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Çмú¿¬±¸±â°ü
  • º´¿ø ¹× Áø´Ü ½ÇÇè½Ç
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷

Á¦10Àå ¾Æ¸Þ¸®Ä« À¯ÀüÀÚ ÆÐ³Î ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯ÀüÀÚ ÆÐ³Î ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« À¯ÀüÀÚ ÆÐ³Î ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Agilent Technologies, Inc.
  • Arizona Oncology
  • ARUP Laboratories
  • Becton, Dickinson, and Company
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • Blueprint Genetics Oy by Quest Diagnostics
  • CENTOGENE NV
  • Cepheid by Danaher Corporation
  • Eurofins Genomics LLC
  • Everything Genetic Ltd.
  • Fulgent Genetics
  • Genewiz by Azenta Life Sciences
  • Guardant Health, Inc.
  • Illumina Inc.
  • myGenomics
  • Myriad Genetic Laboratories Inc.
  • NanoString Technologies, Inc.
  • Natera, Inc.
  • Novogene Co, Ltd.
  • PrimBio Research Institute
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience
JHS 24.12.17

The Gene Panel Market was valued at USD 3.11 billion in 2023, expected to reach USD 3.41 billion in 2024, and is projected to grow at a CAGR of 9.99%, to USD 6.06 billion by 2030.

Gene panels are collections of genes examined simultaneously using next-generation sequencing technologies. They are crucial for identifying genetic mutations linked to various diseases, enabling precise and personalized medicine. The necessity of gene panels arises from their capacity to offer rapid, comprehensive genetic insights, improving diagnostic accuracy and treatment personalization. Applications span multiple domains, including oncology, where they facilitate mutation detection for targeted therapies, and genetic disorders for early diagnosis. In end-use scenarios, gene panels are vital in clinical diagnostics, research institutions, and hospitals, particularly within oncology and rare disease sectors.

KEY MARKET STATISTICS
Base Year [2023] USD 3.11 billion
Estimated Year [2024] USD 3.41 billion
Forecast Year [2030] USD 6.06 billion
CAGR (%) 9.99%

Market growth is influenced by rising demand for personalized medicine, advancements in sequencing technologies, and increasing research funding. The growing incidence of genetic disorders and cancer augments demand for effective diagnostic tools like gene panels. The latest opportunities lie in developments of panels for more extensive gene detection and enhancements in accuracy and speed. There is a burgeoning interest in direct-to-consumer genetic testing as awareness of personal genomics rises. Recommendations for businesses include investing in expanding the scope of gene panels to encompass more rare diseases and collaborating with healthcare providers to integrate testing into regular practice.

However, challenges such as high costs of testing, complex data interpretation, and regulatory landscapes hamper market growth. The intricate nature of genetic data necessitates skilled personnel, and the variability in regulatory standards across regions can impede global market expansion. Innovative areas for business growth include developing cost-effective, comprehensive panels and employing artificial intelligence for data analysis to streamline interpretation processes. Companies can focus on creating panels that target not only disease-causing mutations but also pharmacogenomics for better drug responses, reinforcing the trend towards personalized medicine. Moreover, expanding partnerships with biotech firms and academic research institutions could propel advancements and market expansion effectively. Adapting to and anticipating regulatory changes proactively can also provide a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gene Panel Market

The Gene Panel Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surging prevalence of genetic disorders and rare disease
    • Growing need for the personalized medicines
    • Rapid adoption of multi-gene panel testing in oncology practice
  • Market Restraints
    • Issues in ensuring the security of genetic data
  • Market Opportunities
    • Favorable government initiatives for population sequencing
    • Introduction of new gene panels based on next-generation sequencing for clinical research
  • Market Challenges
    • Accuracy concerns and standardization issues in diagnostic testing

Porter's Five Forces: A Strategic Tool for Navigating the Gene Panel Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gene Panel Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gene Panel Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gene Panel Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gene Panel Market

A detailed market share analysis in the Gene Panel Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gene Panel Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gene Panel Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gene Panel Market

A strategic analysis of the Gene Panel Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gene Panel Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Arizona Oncology, ARUP Laboratories, Becton, Dickinson, and Company, BGI Group, Bio-Rad Laboratories, Inc., Blueprint Genetics Oy by Quest Diagnostics, CENTOGENE N.V., Cepheid by Danaher Corporation, Eurofins Genomics LLC, Everything Genetic Ltd., Fulgent Genetics, Genewiz by Azenta Life Sciences, Guardant Health, Inc., Illumina Inc., myGenomics, Myriad Genetic Laboratories Inc., NanoString Technologies, Inc., Natera, Inc., Novogene Co, Ltd., PrimBio Research Institute, Qiagen N.V., Thermo Fisher Scientific Inc., and Twist Bioscience.

Market Segmentation & Coverage

This research report categorizes the Gene Panel Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technique, market is studied across Microarray, Next-Generation Sequencing, and Polymerase Chain Reaction.
  • Based on Product, market is studied across Test Kits and Testing Services.
  • Based on Application, market is studied across Cancer Diagnostics, Genetic Disorders, Infectious Diseases, and Pharmacogenomics.
  • Based on End-User, market is studied across Academic & Research Institutes, Hospital & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging prevalence of genetic disorders and rare disease
      • 5.1.1.2. Growing need for the personalized medicines
      • 5.1.1.3. Rapid adoption of multi-gene panel testing in oncology practice
    • 5.1.2. Restraints
      • 5.1.2.1. Issues in ensuring the security of genetic data
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable government initiatives for population sequencing
      • 5.1.3.2. Introduction of new gene panels based on next-generation sequencing for clinical research
    • 5.1.4. Challenges
      • 5.1.4.1. Accuracy concerns and standardization issues in diagnostic testing
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gene Panel Market, by Technique

  • 6.1. Introduction
  • 6.2. Microarray
  • 6.3. Next-Generation Sequencing
  • 6.4. Polymerase Chain Reaction

7. Gene Panel Market, by Product

  • 7.1. Introduction
  • 7.2. Test Kits
  • 7.3. Testing Services

8. Gene Panel Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer Diagnostics
  • 8.3. Genetic Disorders
  • 8.4. Infectious Diseases
  • 8.5. Pharmacogenomics

9. Gene Panel Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Hospital & Diagnostic Laboratories
  • 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Gene Panel Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Gene Panel Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Gene Panel Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agilent Technologies, Inc.
  • 2. Arizona Oncology
  • 3. ARUP Laboratories
  • 4. Becton, Dickinson, and Company
  • 5. BGI Group
  • 6. Bio-Rad Laboratories, Inc.
  • 7. Blueprint Genetics Oy by Quest Diagnostics
  • 8. CENTOGENE N.V.
  • 9. Cepheid by Danaher Corporation
  • 10. Eurofins Genomics LLC
  • 11. Everything Genetic Ltd.
  • 12. Fulgent Genetics
  • 13. Genewiz by Azenta Life Sciences
  • 14. Guardant Health, Inc.
  • 15. Illumina Inc.
  • 16. myGenomics
  • 17. Myriad Genetic Laboratories Inc.
  • 18. NanoString Technologies, Inc.
  • 19. Natera, Inc.
  • 20. Novogene Co, Ltd.
  • 21. PrimBio Research Institute
  • 22. Qiagen N.V.
  • 23. Thermo Fisher Scientific Inc.
  • 24. Twist Bioscience
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦